Contribution of IL22 to experimental skin inflammation

Progress in Inflammation Research: ‘IL17, IL22 and Their Producing Cells: Role in Inflammation and Autoimmunity’, Springer Basel, 305‐317.

LECRON JC., PARIS I., BERNARD FX., MOREL F. (2013)

Laboratoire Inflammation, Tissus Epithéliaux et Cytokines, UPRES EA4331, Pôle Biologie Santé, Université de Poitiers, France.
CHU de Poitiers, France.
Bioalternatives, Gençay, France.

Abstract

The skin represents the first line defense against various stresses including pathogens and injuries. Cutaneous homeostasis and defenses are maintained by permanent cross talk among dermal fibroblasts, keratinocytes, and cells of the immune system residing in or recruited to skin, through the production of cytokines and chemokines. In this chapter, we discuss the biological effects of IL22 on keratinocytes and more particularly its position in skin inflammation and in the development of inflammatory skin diseases such as psoriasis.
Focused on in vitro human models, we present the mechanisms of action of IL22 as well as its involvement in structure, metabolism, differentiation, chemotaxis, antibacterial activity, innate immunity, and tissue remodeling of epidermis. Pertinence of these models is debated by confrontation to structural and molecular characteristic of psoriatic skin. IL22 belongs to cytokine milieu impregnating inflammatory skin. We attempt to delineate more precisely its unique position among other proinflammatory cytokines and in the synergistic effect of these cytokines. Finally, we consider the local cell sources of IL22 in the psoriatic skin.
We question potential new therapeutic strategies for psoriasis focused on more specific and downstream targets, i.e., keratinocyte-targeting cytokines, rather than on modulating producing cells by immunosuppression.

© Springer International Publishing AG, Part of Springer Science+Business Media

KEYWORDS: Immunology; Receptors; Cytokines and Growth Factors ; Infectious Diseases; Cancer Research

Check out Bioalternatives’ updates and experience new testing ideas

  • Bioassays, models and services
  • Posts and publications
  • Events
  • The legal basis for the processing is consent. Your e-mail address will only be communicated to the following recipients: the departments concerned and authorised by QIMA LIFE SCIENCE. This data is kept for as long as you are registered to the newsletter.

    You can access your data, rectify it, request its deletion or exercise your right to limit the processing of your data, withdraw your consent to the processing of your data at any time, oppose the processing of your data and you have a right to the portability of your data.

    Visit cnil.fr for more information on your rights.
    You can exercise all your rights using the following linkGestion des droits or by writing to dpo-qima@agencergpd.eu. If you feel, after contacting us, that your "Informatique et Libertés" rights are not being respected, you can submit a complaint to the CNIL.

  • The information collected on this form is recorded in a file used by QIMA Life Sciences to send you its newsletter.